INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co.'s (LLY) basal insulin peglispro or BIL consistently demonstrated superior hemoglobin A1c (HbA1c) reduction in people with type 2 diabetes compared to insulin glargine across three Phase III trials. The results were presented today at the 75th American Diabetes Association or ADA Scientific Sessions in Boston.
The trials compared BIL and insulin glargine in three common type 2 patient populations: those not previously using insulin (IMAGINE-2), those using basal insulin with mealtime insulin (IMAGINE-4) and those currently using a basal insulin (IMAGINE-5).
Additional data from IMAGINE-2, IMAGINE-4 and IMAGINE-5 showed that more patients taking BIL consistently met the ADA's recommended HbA1c target of less than 7 percent. A greater percentage of BIL-treated patients also reported less nocturnal hypoglycemia compared to those on insulin glargine. Rates of total and severe hypoglycemia did not differ significantly between treatment groups. Patients taking BIL experienced less weight gain than patients taking insulin glargine in IMAGINE-2 and IMAGINE-4.
In all three clinical trials, patients taking BIL had an increase in the liver enzyme ALT (alanine aminotransferase), and triglyceride levels were higher than in patients treated with insulin glargine. Liver fat content was higher after treatment with BIL compared to insulin glargine in subsets of patients studied from IMAGINE-2 and IMAGINE-5.
Copyright RTT News/dpa-AFX
© 2015 AFX News
